{"filing":{"accession_number":"0001193125-26-267472","cik":"0001810182","ticker":"ALXO","company_name":"ALX ONCOLOGY HOLDINGS INC","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"alxo-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312526267472/alxo-20260610.htm"},"events":[{"id":5350,"run_id":4687,"accession_number":"0001193125-26-267472","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6224,"accession_number":"0001193125-26-267472","item_number":"5.07","item_title":"Submission of matters to a vote of security holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:03:15.835525+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6224,"accession_number":"0001193125-26-267472","item_number":"5.07","item_title":"Submission of matters to a vote of security holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:03:15.835525+00:00","company_name":"ALX ONCOLOGY HOLDINGS INC","ticker":"ALXO","filing_date":"2026-06-11"}]}